Clincierge™ Expands Clinical Concierge Services for Trial Participants and Families into 30th Country

Article

Applied Clinical Trials

PHILADELPHIA, July 28, 2015 /PRNewswire/ -- Clincierge™, the leading provider of specialized services and personalized support designed to overcome barriers to patient participation in clinical studies, today announced the expansion of its innovative "patient concierge" service into Cyprus. This event marks the 30th country where the company's high-touch, one-on-one services for patients and families are available to aid companies conducting clinical trials increase trial enrollment and improve patient retention, thus helping to ensure that costly studies complete on time and on budget.

"Since its inception two years ago, Clincierge has supported multiple studies internationally for pharmaceutical companies and contract research organizations with great success and overwhelming positive feedback from patients, research site personnel and sponsors," said Scott Gray, Clincierge chief executive officer. "By offering patients and their families personalized services in their own language from their own in-country coordinator, and providing patients ease-of-access to research sites, studies using Clincierge have seen increased enrollment and have maintained drop-out rates of less than 5%. Moreover, the cost of incorporating Clincierge services has averaged less than 1% to overall clinical trial costs."

Offering personalized support to trial participants and their families alleviates anxieties about trial-related travel, expenses and other issues that can get in the way of patients enrolling and staying in a clinical study. "The ultimate goal of Clincierge is to aid drug developers in reducing overall clinical testing time and cost by making clinical trials more patient-centric, thus helping ensure that new treatments get to the market and to patients who need them as swiftly as possible," Mr. Gray concluded.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.